TPX Medik appointed as the exclusive distributor of GastroPanel® test in Malaysia
Biohit Oyj press release 14.12.2020 at 9.30 local time (EEST)
Biohit Oyj and TPX Medik (Selangor, Malaysia) have signed a contract on the exclusive rights for distribution of Biohit GastroPanel® test in Malaysia. This is a major milestone in the global expansion strategy of Biohit Oyj, its flagship test now entering into the growing market of Malaysia.
GastroPanel® biomarker test is a unique innovation of Biohit Oyj, designed for the first-line diagnosis of all patients with upper abdominal symptoms (dyspepsia) and reflux complaints (1,2). This first non-invasive diagnostic test on the market confirms or excludes the presence of Helicobacter pylori (Hp) infection and atrophic gastritis (AG)(1,2,3).
At the same time, GastroPanel® is the only test monitoring the acid output regulatory mechanism in the stomach. Hp and AG are the two most important risk conditions for gastric cancer (GC), and because of this, GastroPanel® is also particularly suitable for population-based screening of asymptomatic individuals for the risk of GC, as confirmed in several studies from the high- and low-risk countries (4-7). In Malaysia, GC remains to be a major disease burden, albeit the incidence rates in both genders are declining.
CEO Max Low Jin Ren, TPX Medik:“TPX Medik has a vision, according to which the company objective is to be the most innovative health care supply chain provider offering high-quality, certified medicines to our clients by ensuring fast, safe and customized transportation throughout South East Asia. Our mission is to strive to be the most reliable pharmaceutical wholesaler and medical consultancy with our extensive network of partners and suppliers so that everyone can have equal access to health care. The Biohit GastroPanel® test, being the first and still the only-on-market non-invasive diagnostic test for stomach health and disease, has a perfect match to both our vision and our mission. We are confident that this unique and innovative test will receive a favorable and enthusiastic acceptance in Malaysia, where people are more and more conscious about their health and also increasingly aware of the great potential that a modern diagnostic technology has to offer.”
CEO Semi Korpela, Biohit Oyj:“The ongoing coronavirus pandemic does not respect geographic boundaries, but burdens the national health care in all continents, Malaysia and Finland included. Many non-urgent examinations and treatments need to be cancelled or postponed. This applies also to invasive gastroscopies in diagnosis of dyspepsia, and therefore AG with an increased risk of GC (and other important sequels) might go unnoticed, which bears a risk of increasing unnecessary GC deaths. This potentially serious development could be interfered by GastroPanel® examination for timely identification of the patients with AG and at increased risk for GC (and other serious clinical sequels). During these exceptional times, GastroPanel® might also be a useful adjunct in coronavirus testing of elderly people, because (in most cases) asymptomatic AG might predispose these senior citizens also to coronavirus infection and/or to more severe outcomes of the disease. We are very glad to start co-operation with TPX Medik.”
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
TPX Medik in brief
TPX Medik is part of Teraju X Holdings. Since the merge in the early 2020, Teraju X Holdings has become an established group in pharmaceutical industry with a continuous and diversifications of the services. This is to achieve our mission where we want to provide not only accessibility and efficient medication and treatment, TPX Medik also aspire to provide a high quality treatments, developing and providing a better solution while improving the health of Malaysians, ultimately the whole populations in this world. Through its five years of operations on a global platform, the group has acquired the expertise to offer special solutions to hospitals and various health care providers. Having a deep understanding of pharmaceutical products and supplies has enabled the group to source any products regardless of the product’s origins and situation.
References
1. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K and Sung J: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136-147.
2.Syrjänen K, Eskelinen M, Peetsalu A, Sillakivi T, Sipponen P, Härkönen M, Paloheimo L, Mäki M, Tiusanen T, Suovaniemi O, DiMario F, Fan ZP. GastroPanel® Biomarker Panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res 2019;39:1091-1104.
3.Syrjänen K: A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36: 5133-5144.
4.Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A and Bazzoli F: Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017;46:1-11.
5.Kurilovich SA, Belkovets AV, Reshetnikov OV, Openko TG, Malyutina SK, Ragino YI, Scherbakova LV, Leja M, Paloheimo L, Syrjänen K, Voevoda MI. Stomach-specific biomarkers (GastroPanel) can predict the development of gastric cancer in Caucasian population: A longitudinal nested case-control study in Siberia. Anticancer Res 2016;36:247-254.
6.Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X and Yuan Y: A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: A multi-phase study. Am J Gastroenterol 2017;112:704-715.
7.Cai Q, Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y et al. and Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA). Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut 2019;0:1–12. doi:10.1136/gutjnl-2018-317556
8.Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand J Gastroenterol 2009; 44:912-25.
9.Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol meta¬bolism. Genes Nutr 2010;5:121-128.
10.Jeong Soo Ahn, Chun-Sick Eom, Christie Y Jeon, Sang Min Park. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol 2013 April 28; 19(16): 2560-2568.
11.Hellström PM, Hendolin P, Kaihovaara P, Kronberg L, Meierjohann A, Millerhov A, Paloheimo L, Sundelin H, Syrjänen K, Webb D-L, Salaspuro M. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacterassociated atrophic gastritis. Scand. J. Gastroenterol 2016;52:230-237.
12.Lachenmeier DW, Salaspuro M. ALDH2-deficiency as genetic epidemiologic and biochemical model for the carcinogenicity of acetaldehyde. Regul Toxicol Pharmacol. 2017;86:128-136.
13.www.biohithealthcare.com/ About Us /Investors/Stock Exchange Releases: 2017-09-11T07:30:00Z – An important patent granted to Biohit Acetium® Capsule in Japan
14. www.biohithealthcare.com/additional-information4
15. www.biohithealthcare.com/ News/Links: State of the art GastroPanel and Acetium innovations for the unmet need